Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Feb 15;2012(2):CD004407.
doi: 10.1002/14651858.CD004407.pub3.

Vaccines for measles, mumps and rubella in children

Vittorio Demicheli  1 , Alessandro Rivetti, Maria Grazia Debalini, Carlo Di Pietrantonj
Affiliations
Meta-Analysis

Vaccines for measles, mumps and rubella in children

Vittorio Demicheli et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Mumps, measles and rubella (MMR) are serious diseases that can lead to potentially fatal illness, disability and death. However, public debate over the safety of the trivalent MMR vaccine and the resultant drop in vaccination coverage in several countries persists, despite its almost universal use and accepted effectiveness.

Objectives: To assess the effectiveness and adverse effects associated with the MMR vaccine in children up to 15 years of age.

Search methods: For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 2), which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, PubMed (July 2004 to May week 2, 2011) and Embase.com (July 2004 to May 2011).

Selection criteria: We used comparative prospective or retrospective trials assessing the effects of the MMR vaccine compared to placebo, do nothing or a combination of measles, mumps and rubella antigens on healthy individuals up to 15 years of age.

Data collection and analysis: Two review authors independently extracted data and assessed methodological quality of the included studies. One review author arbitrated in case of disagreement.

Main results: We included five randomised controlled trials (RCTs), one controlled clinical trial (CCT), 27 cohort studies, 17 case-control studies, five time-series trials, one case cross-over trial, two ecological studies, six self controlled case series studies involving in all about 14,700,000 children and assessing effectiveness and safety of MMR vaccine. Based on the available evidence, one MMR vaccine dose is at least 95% effective in preventing clinical measles and 92% effective in preventing secondary cases among household contacts.Effectiveness of at least one dose of MMR in preventing clinical mumps in children is estimated to be between 69% and 81% for the vaccine prepared with Jeryl Lynn mumps strain and between 70% and 75% for the vaccine containing the Urabe strain. Vaccination with MMR containing the Urabe strain has demonstrated to be 73% effective in preventing secondary mumps cases. Effectiveness of Jeryl Lynn containing MMR in preventing laboratory-confirmed mumps cases in children and adolescents was estimated to be between 64% to 66% for one dose and 83% to 88% for two vaccine doses. We did not identify any studies assessing the effectiveness of MMR in preventing rubella.The highest risk of association with aseptic meningitis was observed within the third week after immunisation with Urabe-containing MMR (risk ratio (RR) 14.28; 95% confidence interval (CI) from 7.93 to 25.71) and within the third (RR 22.5; 95% CI 11.8 to 42.9) or fifth (RR 15.6; 95% CI 10.3 to 24.2) weeks after immunisation with the vaccine prepared with the Leningrad-Zagreb strain. A significant risk of association with febrile seizures and MMR exposure during the two previous weeks (RR 1.10; 95% CI 1.05 to 1.15) was assessed in one large person-time cohort study involving 537,171 children aged between three months and five year of age. Increased risk of febrile seizure has also been observed in children aged between 12 to 23 months (relative incidence (RI) 4.09; 95% CI 3.1 to 5.33) and children aged 12 to 35 months (RI 5.68; 95% CI 2.31 to 13.97) within six to 11 days after exposure to MMR vaccine. An increased risk of thrombocytopenic purpura within six weeks after MMR immunisation in children aged 12 to 23 months was assessed in one case-control study (RR 6.3; 95% CI 1.3 to 30.1) and in one small self controlled case series (incidence rate ratio (IRR) 5.38; 95% CI 2.72 to 10.62). Increased risk of thrombocytopenic purpura within six weeks after MMR exposure was also assessed in one other case-control study involving 2311 children and adolescents between one month and 18 years (odds ratio (OR) 2.4; 95% CI 1.2 to 4.7). Exposure to the MMR vaccine was unlikely to be associated with autism, asthma, leukaemia, hay fever, type 1 diabetes, gait disturbance, Crohn's disease, demyelinating diseases, bacterial or viral infections.

Authors' conclusions: The design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-marketing, are largely inadequate. The evidence of adverse events following immunisation with the MMR vaccine cannot be separated from its role in preventing the target diseases.

PubMed Disclaimer

Conflict of interest statement

Dr Jefferson in 1999 acted as an ad hoc consultant for a legal team advising MMR manufacturers.

Update of

References

References to studies included in this review

    1. Ahlgren C, Oden A, Toren K, Andersen O. Multiple sclerosis incidence in the era of measles‐mumps‐rubella mass vaccinations. Acta Neurologica Scandinavica 2009;119(5):313‐20. - PubMed
    1. Ahlgren C, Toren K, Oden A, Andersen O. A population‐based case‐control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology 2009;24(9):541‐52. - PubMed
    1. Beck M, Welsz‐Malecek R, Mesko‐Prejac M, Radman V, Juzbasic M, Rajninger‐Miholic M, et al. Mumps vaccine L‐Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards 1989;17(1):85‐90. - PubMed
    1. Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ 1992;304(6834):1075‐8. - PMC - PubMed
    1. Bertuola F, Morando C, Menniti‐Ippolito F, Cas R, Capuano A, Perilongo G, et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case‐control study in Italy. Drug Safety 2010;33(1):65‐72. - PubMed

References to studies excluded from this review

    1. Akobeng AK, Thomas AG. Inflammatory bowel disease, autism, and the measles, mumps, and rubella vaccine. Journal of Pediatric Gastroenterology and Nutrition 1999;28(3):351‐2. - PubMed
    1. Andre FE. Summary of clinical studies with the Oka live varicella vaccine produced by Smith Kline‐RIT. Biken Journal 1984;27(2‐3):89‐98. - PubMed
    1. Anonymous. Adverse effects of Virivac. Lakartidningen 1982;79(42):3822. - PubMed
    1. Anonymous. Vaccination: news on precautions, contraindications, and adverse reactions. Consultant 1997;37(3):756‐60.
    1. Anonymous. Incidence of measles vaccine‐associated adverse events is low. Drugs & Therapy Perspectives 1999;14(11):13‐6.

References to studies awaiting assessment

    1. Arenz S, Schmitt HJ, Tischer A, Kries R. Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatric Infectious Disease Journal 2005;24(8):697‐9. - PubMed
    1. Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, et al. The risk of seizures after receipt of whole‐cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine 2001;345(9):656‐61. - PubMed
    1. Barrabeig I, Rovira A, Rius C, Munoz P, Soldevila N, Batalla J, et al. Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal 2011;30(1):78‐80. - PubMed
    1. Benke G, Abramson M, Raven J, Thien FC, Walters EH. Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health 2004;28(4):336‐8. - PubMed
    1. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004‐2005 mumps outbreak, England. Emerging Infectious Diseases 2007;13(1):12‐7. - PMC - PubMed

Additional references

    1. Briss PA, Fehrs LJ, Parker RA, Wright PF, Sannella EC, Hutcheson RH, et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine‐induced immunity. Journal of Infectious Diseases 1994;169(1):77‐82. - PubMed
    1. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. Morbidity and Mortality Weekly Report 1997;46:RR‐19. - PubMed
    1. Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, et al. Mumps vaccine performance among university students during a mumps outbreak. Clinical Infectious Diseases 2008;46(8):1172‐80. - PubMed
    1. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clinical Infectious Diseases 2008;47(11):1458‐67. - PubMed
    1. Farrington CP. Control without separate controls: evaluation of vaccine safety using case‐only methods. Vaccine 2004;22(15‐16):2064‐70. - PubMed

References to other published versions of this review

    1. Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004407.pub2] - DOI - PubMed

Publication types

MeSH terms

Substances